NHS Operational Planning and Contracting Guidance 2019/20

NHS England | January 2019 | NHS Operational Planning and Contracting Guidance 2019/20

This is the full guidance, building on the first part published in December 2018. It accompanies five-year indicative CCG allocations and sets out the trust financial regime for 2019/20, alongside the service deliverables including those arising from year one of the Long Term Plan. CCGs and trusts should take action from April 2019 to begin implementing the measures set out in the LTP (Source: NHS England).

NHS Operational Planning and Contracting Guidance 2019/20

Advertisements

Evidence Based Interventions clinical commissioning guidance

This summer, the Academy of Medical Royal Colleges, NICE, NHS Clinical Commissioners and NHS England and NHS Improvement joined forces to consult on how best to reduce the number of inappropriate interventions provided by the NHS. The consultation focused on 17 interventions resulting in clinical commissioning guidance for when the 17 interventions should be commissioned and offered.

The guidance will come into effect from 1 April 2019, however, changes to local systems and processes will need to be made ahead of that date to prevent any unintended consequences. The guidance and supporting information can be found on the NHS England Website

Cardiovascular disease prevention: cost-effective commissioning

This guidance has been produced to help commissioners provide cost-effective interventions to prevent cardiovascular disease | Public Health England

rope-1468951_1920

This return on investment tool synthesises evidence on the effectiveness and associated costs for interventions aimed at preventing cardiovascular disease in individuals with associated risk factors.

The web-based tool allows the user to answer the following questions:

  • what happens when I improve detection or management of key CVD risk factors?
  • what happens when I improve usage of the key interventions for people at risk of CVD?

The tool is supported by:

  • an accompanying report detailing how the tool was constructed as well as the results of exemplar analyses (which simulate scaling up interventions to 100% of the eligible populations)
  • a user guide showing the user how to run their own scenarios through the model
  • a database of interventions providing an Excel summary of key evidence used in the tool.
  • a technical appendix which details the methodology behind the tool

Full detail at Public Health England

Full document: Cardiovascular Disease Prevention Return on Investment Tool: Final Report

 

 

Familial Hypercholesterolaemia: implementation guide

PHE, NICE, NHS England, HEARTUK  & The  British Heart Foundation|  August 2018 | Familial Hypercholesterolaemia: implementation guide

A new implementation guide, written collaboratively by PHE, NICE, NHS England, HEARTUK and the British Heart Foundation, highlights that improving care for those with Familial Hypercholesterolaemia will need a co-ordinated effort and a whole-system approach. 

Familial Hypercholesterolaemia (FH) is a genetic predisposition which more than 85% of people with FH in the UK are unaware that they have the condition and that they are at risk of premature heart disease. Untreated, people aged 20-39 with FH have a 100-fold increased risk of death from heart disease compared to those of a similar age without FH, and so early identification and treatment are absolutely crucial.

The new guide: Familial Hypercholesterolaemia: implementation guide, t

This guide IS aimed at local commissioners and service providers. By searching GP records for those at risk and offering DNA testing to family members of people diagnosed with FH we can start to address this hidden burden.

This implementation guide aims to provide practical support to organisations, helping them to identify the gaps in the provision of FH services in their local area, and helping them address these gaps in line with the recently updated NICE guidance.

 

It includes:

  • a summary of recommendations from the recent update of the document
  • an outline of national and European policy documents
  • best practice case studies

(Source: PHE, NICE, NHS England, HEARTUK  & The  British Heart Foundation)

Implementation Guide: Familial Hypercholesterolaemia Implementing a systems approach to detection and management

Guidance for CCGs on prescription for conditions that over the counter items treat

NHS England  | April 2018 | Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs 

New guidance from NHS England for Clinical Commissioning Groups (CCGs ) to take the proposed conditions for which over the counter items (OTC)  should not routinely be prescribed in primary care guidance into account in formulating local polices, and for prescribers to reflect local policies in their prescribing practice. Spending on OTC items for the year up to June 2017 was  approximately £569 million on prescriptions for medicines, which could otherwise be purchased over the counter from a pharmacy and/or other outlets such as petrol stations or supermarkets.drug-icon-2316244_1280
These prescriptions include items for a condition:

  • That is considered to be self-limiting and so does not need treatment as it will heal or be cured of its own accord;
  •  Which lends itself to self-care i.e. the person suffering does not normally need to seek medical advice and can manage the condition by purchasing OTC items directly.
    These prescriptions also include other common items:
  •  That can be purchased over the counter, sometimes at a lower cost than that which would be incurred by the NHS;
  •  For which there is little evidence of clinical effectiveness.

NHS England gives the example that for every  £1 million saved on prescriptions for OTC items could fund :

39 more community nurses; or

  •  270 more hip replacements; or
  •  66 more drug treatment courses for breast cancer; or
  •  1000 more drug treatment courses for Alzheimer’s; or
  • 1040 more cataract operations

The full guidance can be read at NHS England 

The Improving Access to Psychological Therapies (IAPT) Pathway for People with Long-term Physical Health Conditions and Medically Unexplained Symptoms  

NHS England & NHS Improvement  | March 2018  | The Improving Access to Psychological Therapies (IAPT) Pathway for People with Long-term Physical Health Conditions and Medically Unexplained Symptoms

NHS England & NHS Improvement  have developed, The Improving Access to Psychological Therapies (IAPT) Pathway for People with Long-term Physical Health Conditions and Medically Unexplained Symptoms. This guidance has been produced to support Clinical Commissioning Groups CCGs in expanding Improving Access to Psychological Therapies by commissioning (IAPT) services integrated into physical healthcare pathways.  To facilitate this expansion, it sets out the treatment pathway that that underpins the access and waiting time standards, which all services should seek to measure themselves against.

iapt
Image source: england.nhs.uk

From April 2018 all CCGs are expected to expand Improving Access to Psychological Therapies by commissioning (IAPT) services integrated into physical healthcare pathways (NHS England & NHS Improvement).

The guidance can be read at NHS England 

New data protection legislation affecting all NHS organisations

The General Data Protection Regulation (GDPR) is set to replace the existing Data Protection Act on 25 May 2018. It will require all organisations, which process personal data – including CCGs, to meet higher data protection standards.

Some of the new requirements of GDPR will be appointing a data protection officer, the ability to demonstrate that you are complying with the new law and higher penalties for those not following the rules.

The Information Commissioners Office has produced a package of tools and resources to help you get ready. These resources include:

ico
Image source: ico.org.uk/

Further information can be found on the Information Commissioner’s Office’s website.